Allergic respiratory disorders—such as allergic rhinitis, chronic rhinosinusitis, and nasal polyps—are characterized by activation of inflammatory pathways and the production of immunoglobulin E (IgE). Collectively, these types of diseases contribute to substantial morbidity and loss of productivity in affected individuals. Although existing treatments—including nasal and inhaled corticosteroids, bronchodilators, leukotriene antagonists, decongestants, mast cell stabilizers, allergen immunotherapies, and biologics—address the needs of many patients, these therapies prove inadequate for some patients. Asthma therapies such as Roche / Novartis’s well-known anti-IgE agent Xolair are being tested for these disorders. Novel therapies with distinct modes of action and/or targets are also in clinical development to expand treatment options for inadequately controlled patients. The availability of these emerging therapies has the potential to significantly improve patient health outcomes and quality of life.
QUESTIONS ANSWERED
Geographies– United States and EU5
Primary Research– Interviews with ten allergic respiratory disorder experts (allergists, pulmonologists, otolaryngologists) from the United States and Europe
Key Insights Provided
PRODUCT DESCRIPTION
DRG’s Special Topics reports assess key trends in dynamic disease areas. This report on allergic respiratory disorders will help developers gain needed insight into the clinical development of therapies that could shape the future of this market.